Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Core Viewpoint - Dr. Reddy's has announced the acceptance of its Biologics License Application (BLA) for the proposed interchangeable biosimilar, Abatacept, by the USFDA [1] Group 1 - The USFDA will review the BLA submitted by Dr. Reddy's for Abatacept, which is a significant step towards potential market entry [1]